Sutro Biopharma
STRO
58 hedge funds and large institutions have $134M invested in Sutro Biopharma in 2019 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 20 increasing their positions, 15 reducing their positions, and 3 closing their positions.
300% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 3
33% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 15
18% more funds holding
Funds holding: 49 → 58 (+9)
5% more capital invested
Capital invested by funds: $128M → $134M (+$6.55M)
0.24% more ownership
Funds ownership: 4.92% → 5.15% (+0.24%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$3.55M |
| 2 |
BlackRock
New York
|
+$2.52M |
| 3 |
State Street
Boston,
Massachusetts
|
+$675K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$538K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$421K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.35M |
| 2 |
SCM
Sio Capital Management
New York
|
-$658K |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$571K |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$518K |
| 5 |
PCM
Pentwater Capital Management
Naples,
Florida
|
-$298K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
BNP Paribas Financial Markets
Paris,
France
| $13.4K | -$3.75K | -34 | -22% |
|
|
CSS
52
Cubist Systematic Strategies
Stamford,
Connecticut
| $11K | +$10.6K | +96 | New |
|
|
PCM
53
Prelude Capital Management
New York
| $10K | +$10K | +91 | New |
|
54
Bank of Montreal
Toronto,
Ontario, Canada
| $10K | +$10.1K | +92 | New |
|
55
Morgan Stanley
New York
| $9K | -$1.76K | -16 | -16% |
|
|
PAM
56
Panagora Asset Management
Boston,
Massachusetts
| $9K | +$9.15K | +83 | New |
|
|
AIP
57
Ameritas Investment Partners
Lincoln,
Nebraska
| $6K | – | – | – |
|
|
AG
58
Advisor Group
Phoenix,
Arizona
| $2K | – | – | – |
|
|
59
Alyeska Investment Group
Chicago,
Illinois
| – | -$571K | -5,015 | Closed |
|
|
ACP
60
Acuta Capital Partners
Redwood City,
California
| – | -$518K | -4,550 | Closed |
|
|
CCA
61
Catalyst Capital Advisors
Huntington,
New York
| – | -$6K | -50 | Closed |
|
STRO Hedge Fund Activity: Q2 2019 in Review
58 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Sutro Biopharma (STRO) for Q2 2019, worth a combined $134M — up 5.1% from $128M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new STRO positions and 3 closed out — a net gain of 9 holders — while 20 added to existing stakes and 15 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $3.55M. The largest seller was Fidelity Investments, cutting an estimated $1.35M.
- 58 institutional investors held Sutro Biopharma (STRO) as of Q2 2019, up from 49 in Q1 2019.
- Funds reported $134M of Sutro Biopharma stock for Q2 2019, up 5.1% quarter-over-quarter.
- 12 funds opened new Sutro Biopharma positions in Q2 2019 and 3 closed out, a net change of +9 holders.
- The largest Sutro Biopharma buyer in Q2 2019 was Point72 Asset Management, an estimated $3.55M added.
- The largest Sutro Biopharma seller in Q2 2019 was Fidelity Investments, an estimated $1.35M sold.
Based on aggregated 13F filings for Q2 2019.